Fate Therapeutics Inc
Suletud
SektorTervishoid
1.95 3.17
Ülevaade
Aktsiahinna muutus
24h
Min
1.8900000000000001
Max
2.01
Sissetulek | 1.2M -31M |
|---|---|
Müük | -70K 1.3M |
Aktsiakasum | -0.26 |
Kasumimarginaal | -2,402.848 |
Töötajad | 161 |
EBITDA | 14M -28M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +151.58% upside |
Järgmine tulemuste avaldamine | 10. aug 2026 |
|---|
Turukapital | -19M 234M |
|---|---|
Eelmine avamishind | -1.22 |
Eelmine sulgemishind | 1.95 |
Uudiste sentiment
By Acuity
50%
50%
155 / 342 Pingereas Healthcare
Fate Therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
